BioMarin Pharmaceutical Inc.

BMRN: NasdaqGS
69Total

Lowest reading is at 46 out of 100. All scores are out of 100.

About The Company

CEO

Mr. Alexander Hardy

Market Cap

10.58 Billion USD

Sector

Healthcare

Website

https://www.biomarin.com

Last Update

15/10/2026, 01:01:28

Description

BioMarin Pharmaceutical Inc.

Read More

Strongest readings

  • ✔Financial health is strong (health score 88 out of 100)
  • ✔Debt is low at 0.10 times equity
  • ✔Cashflow and earnings growth is strong (growth score 74 out of 100)
  • ✔Altman-Z score of 5.39 sits above the distress range

Weakest readings

  • ✘Price-to-earnings of 145.1 is above the market average of 19.6
  • ✘Earnings have fallen this year (-89.03%)
  • ✘The current price sits above estimated fair value (margin of safety -40.32%)
  • ✘Share count has been rising at 1.19% per year

Key Figures

StatusMetricValueReadingMarket avg
✘
Price / earnings (TTM)
145.10x
19.60x
✘
Margin of safety (DCF)
-40.32%
17.95%
✔
Revenue growth (5y average)
13.53%
10.97%
✘
Dividend yield (TTM)
0.00%
1.85%
✘
Share count, per year
1.19%
0.00%
✘Return on capital employed7.22%
10.00%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Valuation

46 / 100

Priced above the market on most measures.

StatusMetricValueReadingMarket avg
✘
Price / earnings
145.10x
19.60x
✔Free cashflow yield6.97%
4.70%
Price / earnings growthN/A1.50x
Price / book1.68x
—
✘
Margin of safety
-40.32%
17.95%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Estimated intrinsic value of 32.66 USD is below the current price of 54.68 USD

Desired Margin Of Safety

0%

▼

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Estimated Fair Value: 47.7 USD ✘

Current Price: 54.7 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.

Growth

74 / 100

Growing faster than the market on most measures.

StatusMetricValueReadingMarket avg
✔
Revenue growth
13.53%
10.97%
✔Earnings growth17.11%
14.48%
✔Cashflow growth31.31%
12.35%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Revenue growth has slowed this year (11.20% against a five year average of 13.53%)
  • ✘Earnings growth has slowed this year (-89.03% against a five year average of 17.11%)
  • ✘Free cashflow growth has slowed this year

Health

88 / 100

Balance sheet covers its obligations.

Measured on Leverage and capital, Funding and liquidity, Earnings quality.

StatusMetricValueReadingThreshold
✔Altman-Z score5.39
3.00
✔Piotroski score5.00
5.00
✔Debt / equity0.10x
0.80x
✔Current ratio5.21x
1.00x
✔Interest coverage45.27x
2.50x
✔Free cashflow / debt1.21x
0.15x
✔Debt / capital0.09x
1.00x

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Management

    69 / 100

    Returns on capital are at or above the market.

    StatusMetricValueReadingMarket avg
    ✘Return on equity5.73%
    15.00%
    ✘Return on capital employed7.22%
    10.00%
    Return on assets4.59%
    —
    Free cashflow return on capital10.61%
    —
    ✔Return on capital, 5y change9.11%
    0.00%
    ✘
    Share count, per year
    1.19%
    0.00%
    ✘Share count, recent0.93%
    0.00%
    Realized buyback returnN/A0.00%
    ✔Goodwill erosion / equity0.00%
    2.00%
    Price volatility, 5 year32.90%
    —

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    • ✔New shares were issued while the value score was 46 out of 100

    Analysts

    not enough data
    StatusMetricValueReadingNeutral
    Analyst opinion scoreN/A50

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Financial History

    Annual figures across the full reporting history we hold.

    Market Peers

    BMRN

    SEC Filings

    Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

    See 35+ Years Annual Reports

    Other Information

    Company Name

    BioMarin Pharmaceutical Inc.

    Currency

    USD

    Beta

    0.238

    Vol Avg

    1940101

    Ceo

    Mr. Alexander Hardy

    Cik

    0001048477

    Cusip

    Exchange

    NasdaqGS

    Full Time Employees

    3221

    Industry

    Biotechnology

    Sector

    Healthcare

    Ipo Date

    Address

    770 Lindaro Street

    City

    San Rafael

    State

    CA

    Country

    United States

    Zip

    94901

    Phone

    415 506 6700

    Analysis Last Updated

    15/10/2026, 01:01:28

    Financial data compiled from SEC EDGAR filings and Yahoo Finance.

    Noticed an error with something on our site?

    Data, not advice. Do your own diligence.

    We Use Cookies